CRISPR Therapeutics AG

Youtube Subscribe

Open: 49.89 Close: 52.01 Change: 2.12

The 9 top things that an AI found about CRISPR Therapeutics AG Company Inc Stock... they will surprise you

Are looking for the most relevant information about CRISPR Therapeutics AG? Investor spend a lot of time searching for information to make investment decisions in CRISPR Therapeutics AG. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CRISPR Therapeutics AG are: CRSP, AG, CRISPR, Therapeutics, share, price, stock, and the most common words in the summary are: therapeutic, crispr, stock, ag, market, price, crsp, . One of the sentences in the summary was: CRISPR Therapeutics AG (CRSP) shares opened at $49.89 …

Concept Map

Semantic Network

Stock Summary

CRISPR Therapeutics AG focuses on developing gene-based medicines for serious diseases. Its lead product candidate is CTX001, an ex vivo CRISpr gene-edited therapy for treating patients suffering from transfusion-dependent beta.

Today's Summary

CRISPR Therapeutics AG (CRSP) shares opened at $49.89 on Friday 04/21/2023 on NAS, this is a gain of 4.08% Compared to the opening price on Friday April 21, the market cap is $4.22 B. Crispr Therapeutic AG trades on the NASDAQ under the ticker symbol CRSP.

Today's News

CRISPR Therapeutics AG (CRSP) Stock Price Today, News, Quotes, FAQs and Fundamentals StockTwits Logo Join the Conversation! Build your trading network Follow your favorite assets Link Your Portfolio and become verified. CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISpr/Cas9-based therapeutics. CRSP shares opened at $49.89 on Friday 04/21/2023 on NAS, this is a gain of 4.08% Compared to the opening price on Friday April 21, the market cap is $4.22 B. Crispr Therapeutics Ag trades on the NASDAQ under the ticker symbol CRSP. The total value of the stock (market capitalization) is $4.09B. CRISPR Therapeutics AG (NASDAQ:CRSP) traded at $51.92 at close of the session on Tuesday, 04/18/23, made a downward move of -4.37% on its previous days price. The put/call ratio of CRSP is 0.56, indicating a bullish outlook. CRISPR Therapeutics AG (NASDAQ:CRSP) shares have outperformed across the wider relevant industry. Investors are excited at the prospect of better dividends despite the companys debt issue. Insiders own 1.49% of the company shares. Cantor Fitzgerald sees CRISPR Therapeutics AG (NASDAQ:CRSP) as an attractive investment option for 2023. Cantor Fitzgerald initiated coverage and gave CRISpr Therapeutic AG an “overweight” rating and a $72.00 price objective. CRISPR Therapeutics AG (CRSP) had 60-Day Put-Call Ratio (Open Interest) of 0.1175 for 2023-04-21. of $49.75 (40.75) on CRSP (CRISPR THERERAPEUTICS AG). CRSP stock price of CRSP is 52.01 USD today. The score for CRSP has a 42, the score of funds assets and Movesregister encompasses support traditiontaker CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $50.31 with a gain of -0.49% from the previous trading session. Investors will be expecting strength from CRISpr Therapeutic AG as it approaches its next earnings release. The company is currently a Zacks Rank #2 (Buy) CRISPR Therapeutics AG stock forecast for the beginning of next year is $ 68.02. CRSP stock forecast was last updated on April 22, 2023 at 20:35. Current sentiment is neutral, with 18 technical analysis indicators signaling bullish signals, and 8 signaling bearish signals. In 2030, CRSP shares are expected to increase by 13136%.

Stock Profile

"CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland."

Keywords

This document will help you to evaluate CRISPR Therapeutics AG without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CRISPR Therapeutics AG are: CRSP, AG, CRISPR, Therapeutics, share, price, stock, and the most common words in the summary are: therapeutic, crispr, stock, ag, market, price, crsp, . One of the sentences in the summary was: CRISPR Therapeutics AG (CRSP) shares opened at $49.89 on Friday 04/21/2023 on NAS, this is a gain of 4.08% Compared to the opening price on Friday April 21, the market cap is $4.22 B. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #crispr #stock #ag #market #price #crsp.

Read more →

Youtube Subscribe

---